Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 192 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 8, 2024 |
| Operating expenses | $176.6M | $158.2M | $102.8M |
| Research and development | $225.3M | $108.8M | $70.1M |
| Selling, general and administrative | $61.6M | $49.4M | $32.7M |
| Operating income | -$176.6M | -$158.2M | -$102.8M |
| Income tax | $515.0K | $310.0K | $236.0K |
| Net income | -$141.2M | -$122.5M | -$89.6M |
| EPS, basic | $-0.80 | $-0.78 | $-0.81 |
| EPS, diluted | $-0.80 | $-0.78 | $-0.81 |
| Weighted shares, basic | 177.6M | 157.9M | 110.2M |
| Weighted shares, diluted | 177.6M | 157.9M | 110.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 8, 2024 |
| Cash and equivalents | $799.6M | $169.5M | $129.8M |
| Short-term investments | $646.6M | $714.0M | $337.5M |
| Total current assets | $1.57B | $891.2M | $473.6M |
| Property, plant and equipment | $6.65M | $3.48M | $3.23M |
| Total assets | $1.58B | $903.3M | $482.0M |
| Accounts payable | $13.9M | $8.02M | $4.74M |
| Total current liabilities | $63.3M | $36.0M | $24.7M |
| Total liabilities | $67.5M | $38.5M | $29.1M |
| Shareholders' equity | $1.52B | $864.8M | $453.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Feb 26, 2026 | Feb 27, 2025 | Mar 8, 2024 |
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M |
| Capital expenditures | $3.61M | $1.29M | $2.17M |
| Free cash flow | -$225.8M | -$117.9M | -$81.7M |
| Stock-based compensation | $29.0M | $18.8M | $8.19M |
| Investing cash flow | $89.8M | -$358.9M | -$268.3M |
| Financing cash flow | $762.5M | $515.3M | $451.5M |
| Net change in cash | $630.1M | $39.7M | $103.7M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 214.8M | +18.0% | SEC |
| Jul 31, 2026 | 213.9M | +23.8% | SEC |
| Apr 30, 2026 | 213.2M | +23.5% | SEC |
| Feb 15, 2026 | 212.5M | +23.5% | SEC |
| Oct 31, 2025 | 182.0M | +6.0% | SEC |
| Jul 31, 2025 | 172.8M | +0.7% | SEC |
| Apr 30, 2025 | 172.6M | +23.4% | SEC |
| Jan 31, 2025 | 172.0M | +23.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.